top of page

Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity

  • blonca9
  • Nov 18, 2024
  • 1 min read

CEO Pierre Arsѐne describes how the test analyses hepatocyte extracellular vesicles, and how he believes this result surpasses the current standards of testing such as ultrasound and alpha-fetoprotein testing.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page